Advanced Cell Technology Announces Issuance of Patent Covering Dendritic Cells Manufacturing from Renewable Stem Cell Sources
05 September 2014 - 11:17PM
Business Wire
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTCD), a
leader in the field of regenerative medicine, announced today that
the US Patent and Trademark Office (USPTO) has issued U.S. patent
8,822,218 covering methods of manufacturing dendritic cells using a
highly scalable processing involving a readily renewable stem cell
source as the starting materials. The derivation process covered by
the patent provides a means for commercial scale manufacturing of
an allogeneic, off-the-shelf immunotherapy platform.
“The addition of this new patent continues to strengthen our IP
position around core cell therapy components and helps protect our
leading position in the regenerative medicine field,” said Paul K.
Wotton, Ph.D., President and Chief Executive Officer. “It is an
exciting time to be here as we concentrate our efforts on
developing cures for diseases and disorders of the eye and get
ready to initiate phase 2 clinical trials for the treatment of
Stargardt’s macular degeneration (SMD) and age-related macular
degeneration (AMD).”
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., (ACT) is a clinical stage
biotechnology company focused on the development and
commercialization of regenerative medicine and cell therapy
technology. The company’s most advanced products are in clinical
trials for the treatment of dry age-related macular degeneration,
Stargardt’s macular degeneration and myopic macular degeneration.
ACT’s preclinical programs involve cell therapies for the treatment
of other ocular disorders and for diseases outside the field of
ophthalmology, including autoimmune, inflammatory and wound
healing-related disorders. The company’s intellectual property
portfolio includes pluripotent stem cell platforms – hESC and
induced pluripotent stem cell (iPSC) – and other cell therapy
research programs. For more information, visit
www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and
operating results, future growth in research and development
programs, potential applications of our technology, opportunities
for the Company and any other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including
statements containing the words “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates,” and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including: limited operating history,
need for future capital, risks inherent in the development and
commercialization of potential products, protection of our
intellectual property, and economic conditions generally.
Additional information on potential factors that could affect our
results and other risks and uncertainties are detailed from time to
time in the Company’s periodic reports, including our report on
Form 10-K for the year ended December 31, 2013 and our report on
Form 10-Q for the three and six months ended June 30, 2014.
Forward-looking statements are based on the beliefs, opinions, and
expectations of the Company’s management at the time they are made,
and the Company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions,
expectations, or other circumstances should change. Forward-looking
statements are based on the beliefs, opinions, and expectations of
the Company’s management at the time they are made, and the Company
does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the
Company’s clinical trials or other development programs will be
successful.
Investors:Westwicke PartnersJohn R. Woolford,
443-213-0506orPress:Russo PartnersDavid Schull, 858-717-2310